After diagnosed by morphology and cytogenetics especially molecular genetic information may therefore guide treatment in the near future for this low risk subgroup of MDS patients as investigated here. Prognosis of MDS Subtypes RARS, RCMD and RCMD-RS Does Not Differ by Cytomorphologic Criteria but Cytogenetics Allows to Delineate a Subgroup with Inferior Clinical Course, Blood American Society of Hematology 633. The karyotype and Hb level were the only independent prognostically relevant parameters in. To overcome this shortcoming only an increasing panel of new molecular markers in MDS can pave future investigations which presently becomes available by the advanced sequencing techniques. Conclusions: As investigated here in 1082 pts, RARS, RCMD, and RCMD-RS all show high rates of good karyotypes as defined by IPSS and show similar clinical outcomes which clearly supports to skip the RCMD-RS category as done by the WHO in 2008. Mean WBC count differed between all subgroups (RARS: 6.1 RCMD: 4.4 RCMD-RS: 5.3×10(9)/l RARS vs RCMD p80% of patients show a good risk cytogenetic profile making prognostication according to karyotype relevant only in a small subset of patients. Mean age (RARS: 71.8 RCMD: 70.1 RCMD-RS: 72.6 yrs) reached significant difference between RARS vs RCMD (p=0.020) and between RCMD vs RCMD-RS (p=0.004). Results: Sex ratio (male preponderance in all subtypes male/female ratio 1.9 in the whole cohort) did not differ significantly between the 3 MDS subgroups. Cytogenetic risk groups were defined according to the International Prognostic Scoring System (IPSS Greenberg et al., 1997). 555 Fairmount Avenue Towson, MD 21286 Call: 800.346.4075 Visit: Get Directions Contact Us Name First Last Last Email Company Message Website/URL If you are human, leave this field blank. Be sure to submit a complete and signed form and include your full address, so that any reimbursement due can be sent to you. Late claim processing is almost always due to insufficient address or an incomplete claim. Study Design: To investigate the clinical impact and genetic background of these MDS subtypes, we studied outcomes, cytogenetics, and molecular genetics in 1082 de novo MDS pts (153 RARS, 606 RCMD, 323 RCMD with ring sideroblasts ≥15% termed “RCMD-RS“): 703 m/379 f median age, 73.1 yrs 21.0–90.4 yrs. The claim form must be completed by the Insured Person, as neither Towson University nor the provider will do this for you. One aim of this study was to evaluate whether or not a separation with respect to ring sideroblasts is reasonable. In 2008 the WHO classification combined the former categories RCMD (refractory cytopenia with multilineage dysplasia) and RCMD-RS (with ring sideroblasts ≥15%) thus not separating according to ring sideroblasts anymore in MDS with multilineage dysplasia, while the category refractory anemia with ring sideroblasts (RARS) was maintained separately. headquarters: 555 Fairmount Ave, Towson, Maryland, 21286, United States.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |